Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAFTING-2019
2024-515063-66-00Phase 2Authorised
- Sponsor
- Medical University of Gdańsk
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2 trial of nivolumab in classical Hodgkin lymphoma (cHL) (3 arms), sponsored by Medical University of Gdańsk. Primary endpoint: 3-year progression-free survival (PFS) in very low-risk eHL treated with chemotherapy alone. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2024-515063-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515063-66-00.